Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
By J. Apperley, M. Gardembas, J. Melo, R. Russell‐Jones, B. Bain, E. Baxter, A. Chase, J. Chessells, Marie Colombat, C. Dearden and 9 more. New England Journal of Medicine, 2002
609 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/55ad9a5d5a10db3e1f8df225316a2c95b76543b9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- Ching-Hon Pui
- A. D’Andrea
- William E. Evans
- D. Teachey
- Marco A. Marra
- Benjamin L. Ebert
- S. Maude
- Stacey Gabriel
In Hematology
Citations in the corpus
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2005, background): “A kinases is effective in treatment of several cancers (Apperley et al., 2002; Cools et al., 2003; Demetri et al., 2002; Druker et al., 2001; Lynch et al., 2004; Paez et al., 2004).”
- Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia (2012, background): “The identification of a PDGFRB fusion is of clinical importance, as patients with chronic myeloproliferative disease and activating PDGFRB rearrangements show complete hematologic and molecular responses to imatinib treatment (Apperley et al., 2002).”
- Role of platelet-derived growth factors in physiology and medicine. (2008, positive): “Imatinib has also demonstrated clinical efficacy against myeloproliferative diseases involving rearrangements of the PDGFRB gene (Apperley et al. 2002) and dermatofibrosarcoma protuberans (DP), a tumor carrying translocated and activated PDGF-B genes (McArthur et al. 2005).”